CNTNAP1 and chronic myelogenous leukemia, BCR-ABL1 positive: Regarding the choice of a breakpoint peptide for developing a peptide vaccine strategy in Ph+ ALL we are aware that ALL has a much more instability than CML and thus p190 has more probability to undergo mutations.